NanoRepro AG
XETRA:NN6
Intrinsic Value
NanoRepro AG engages in the development, manufacture, and distribution of diagnostic tests and food supplements for home and professional use. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of NN6.
NanoRepro AG's market capitalization is 22.5m EUR.
NN6 stock price is 1.745 EUR.
NN6.
NN6. Open DCF Valuation
NN6. Open Relative Valuation
NN6.
NN6's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
NN6's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 23%.
NN6 has positive Operating Income for the last twelve months.
NN6's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 42% to 23%.
NN6's ROE (Return on Equity) has significantly decreased in the last 3 years from 27% to 8%.
NN6's Revenue has dropped by 33% over the past 12 months.
NN6 has positive Net Income for the last twelve months.
NN6 has very high three-year average ROE (Return on Equity): 28%. The company is very efficient at transforming stockholders' equity into net income.
NN6 has positive Gross Profit for the last twelve months.
NN6 has positive Free Cash Flow for the last twelve months.
NN6 has very high three-year average ROIC (Return on Invested Capital): 64%. The company is very efficient at using invested capital to generate operating income.
NN6's short-term assets (53m EUR) exceed its short-term liabilties (2m EUR).
NN6's long-term assets (53m EUR) exceed its long-term liabilties (2m EUR).
NN6's D/E (Debt to Equity) is very low and is equal to 0.
NN6's Altman Z-Score is very high and is equal to 18.82.
NN6 earns more than enough operating income (7m EUR) to safely cover interest payments on its debt (52k EUR).
Fundamental Analysis
NanoRepro AG
Balance Sheet Decomposition
NanoRepro AG
| Current Assets | 53.2m |
| Cash & Short-Term Investments | 26.5m |
| Receivables | 11.9m |
| Other Current Assets | 14.8m |
| Non-Current Assets | 79.7k |
| Long-Term Investments | 25k |
| PP&E | 460 |
| Intangibles | 54.3k |
| Current Liabilities | 1.8m |
| Accounts Payable | 251.3k |
| Accrued Liabilities | 650 |
| Other Current Liabilities | 1.6m |
| Non-Current Liabilities | 49.8k |
| Other Non-Current Liabilities | 49.8k |
Earnings Waterfall
NanoRepro AG
|
Revenue
|
90.1m
EUR
|
|
Cost of Revenue
|
-66.3m
EUR
|
|
Gross Profit
|
23.7m
EUR
|
|
Operating Expenses
|
-17.2m
EUR
|
|
Operating Income
|
6.5m
EUR
|
|
Other Expenses
|
-2.5m
EUR
|
|
Net Income
|
4m
EUR
|
Free Cash Flow Analysis
NanoRepro AG
What is Free Cash Flow?
NN6 Profitability Score
Profitability Due Diligence
NanoRepro AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
NanoRepro AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
NN6 Solvency Score
Solvency Due Diligence
NanoRepro AG's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Score
NanoRepro AG's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NN6 Price Targets Summary
NanoRepro AG
Shareholder Return
NN6 Price
NanoRepro AG
| Average Annual Return | 116.81% |
| Standard Deviation of Annual Returns | 258.17% |
| Max Drawdown | -91% |
| Market Capitalization | 22.5m EUR |
| Shares Outstanding | 12 903 773 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
NanoRepro AG
Country
Industry
Market Cap
Dividend Yield
Description
NanoRepro AG engages in the development, manufacture, and distribution of diagnostic tests and food supplements for home and professional use. The company is headquartered in Marburg An Der Lahn, Hessen and currently employs 17 full-time employees. The company went IPO on 2012-10-09. The firm is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patients’ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.
You don't have any saved screeners yet
